Amlodipine

Generic Name: Amlodipine

Brand Names: Amlobenz, Azor, Caduet, Dafiro, Exforge, Exforge Hct, Katerzia, Lotrel, Norliqva, Norvasc, Prestalia, Tribenzor, Twynsta, Viacoram

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₅ClN_₂O_₅

CAS Number: 88150-42-9

Unique Ingredient Identifier: 1J444QC288

Background: Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called dihydropyridine calcium channel blockers. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial depression and cardiac conduction abnormalities than other calcium channel blockers .

Amlodipine is commonly used in the treatment of high blood pressure and angina. Amlodipine has antioxidant properties and an ability to enhance the production of nitric oxide (NO), an important vasodilator that decreases blood pressure . The option for single daily dosing of amlodipine is an attractive feature of this drug .

Indication: Amlodipine may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of the following conditions :

• Hypertension

• Coronary artery disease

• Chronic stable angina

• Vasospastic angina (Prinzmetal’s or Variant angina)

• Angiographically documented coronary artery disease in patients without heart failure or an ejection fraction < 40%

Associated Conditions: Cardiovascular Events, Chronic Stable Angina Pectoris, Coronary Artery Disease (CAD), Homozygous Familial Hypercholesterolaemia (HoFH), Hypertension, Hypertension, Essential Hypertension, Mixed Dyslipidemias, Primary Hypercholesterolemia, Vasospastic Angina

Associated Therapies: -

Clinical Trials

Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Aliskiren
Drug: Hydrochlorothiazide (HCTZ)
Drug: Amlodipine
Drug: Placebo

First Posted Date: 2008-10-03

Last Posted Date: 2011-05-09

Lead Sponsor: Novartis

Target Recruit Count: 1191

Registration Number: NCT00765674

Locations: 🇹🇷
Investigative Site, Ankara, Turkey

The Effect of Losartan Versus Amlodipine-based Therapy in Ischemic Stroke (0954-338)(COMPLETED)

Phase 4

Completed

Conditions: Ischemic Stroke

Interventions: Drug: amlodipine
Drug: losartan

First Posted Date: 2008-09-18

Last Posted Date: 2013-10-23

Lead Sponsor: Taipei Veterans General Hospital, Taiwan

Target Recruit Count: 40

Registration Number: NCT00754429

Efficacy of a Combination of Amlodipine/Valsartan on 24H Blood Pressure Control With One Nocturnal or Diurnal Intake a Day

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: Amlodipine
Drug: Valsartan

First Posted Date: 2008-06-18

Last Posted Date: 2011-05-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 478

Registration Number: NCT00700271

Locations: 🇹🇳
Investigative sites in Tunisia, Tunisia, Tunisia
🇫🇷
Investigative sites in France, Paris, France

Safety, Tolerability, and Efficacy of Once Daily Amlodipine/Valsartan 5/80 as Compared to Amlodipine/Valsartan 5/40 or to Amlodipine 5 mg Monotherapy in Patients 65 Years of Age and Older With Essential Hypertension

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Amlodipine 5 mg
Drug: Valsartan 80 mg
Drug: Valsartan 40 mg
Drug: Placebo

First Posted Date: 2008-06-17

Last Posted Date: 2011-06-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 965

Registration Number: NCT00699192

Locations: 🇮🇹
Investigative site Italy, Rome, Italy
🇨🇿
Investigative sites Czech Republic, Praha, Czech Republic
🇸🇪
Investigative site Sweden, Malmo, Sweden

and more 12 locations